Avalon GloboCare to Launch Online Sales of KetoAir Breathalyzer in the United Kingdom

Rhea-AI Summary

Avalon GloboCare (NASDAQ: ALBT) announced the launch of its KetoAir™ breathalyzer device in the United Kingdom, with sales beginning September 1, 2025 through www.KetoAir.uk. The FDA-registered device measures breath acetone concentration to track ketosis and fat metabolism for individuals following ketogenic diets.

The handheld device, manufactured by Qi Diagnostics Limited, features nano-sensor technology and is compatible with both iOS and Android platforms. This UK expansion follows the company's successful U.S. market launch, targeting users pursuing ketogenic lifestyles for weight management, athletic performance, or therapeutic purposes.

[ "Expansion into the UK market broadens geographic footprint", "Product targets growing ketogenic diet market segment", "Device offers cross-platform compatibility (iOS and Android)" ]

Positive

• None.

Negative

• No revenue projections or market size estimates provided
• Dependent on third-party manufacturer Qi Diagnostics Limited

Insights

Medical Technology Analyst

Avalon's KetoAir UK launch expands market reach for their FDA-registered ketosis monitoring device, representing modest international growth.

Avalon GloboCare's announcement to launch its KetoAir™ breathalyzer in the United Kingdom marks the company's first international market expansion for this product following its U.S. introduction. The handheld device measures breath acetone concentration, a biomarker that indicates fat metabolism during ketosis, using nano-sensor technology.

This expansion targets the growing ketogenic diet market in the UK, where consumers use such diets for weight management, athletic performance enhancement, and therapeutic purposes. The device functions as a companion to mobile applications, with compatibility for both major smartphone platforms, creating an accessible consumer health technology ecosystem.

While this geographic expansion represents a positive development, several contextual factors temper its immediate impact. The announcement doesn't include distribution partnerships, retail placement, or projected revenue figures. Additionally, Avalon doesn't manufacture the device themselves – it's produced by Qi Diagnostics Limited – suggesting Avalon operates primarily as a distributor or marketing partner.

The direct-to-consumer online sales model through a dedicated website (KetoAir.uk) indicates a focused but potentially limited distribution strategy. This approach allows Avalon to test market acceptance with minimal infrastructure investment while maintaining higher margins than traditional retail channels would permit.

The ketogenic monitoring device market faces competition from established players and alternative testing methods like blood and urine testing. Without disclosed pricing or comparative advantage details, it's difficult to assess KetoAir's competitive positioning in this specialized health tech segment.

FREEHOLD, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that it will launch the sales of KetoAir™ breathalyzer device and related accessories in the United Kingdom (“UK”). The products will be available for purchase starting September 1, 2025, at www.KetoAir.uk.

KetoAir™ is a handheld breathalyzer designed for ketogenic health management (U.S. Food and Drug Administration registration number: 3026284320). It measures breath acetone concentration (BrAce), a key indicator of fat metabolism and ketosis. The KetoAir™ breathalyzer device is owned and manufactured by Qi Diagnostics Limited, a nanosensor-based diagnostic technologies company. Intended for users pursuing ketogenic diets for weight loss, athletic performance, or therapeutic purposes, the device utilizes nano-sensor technology to provide real-time insights. KetoAir™ is compatible with both Apple and Android devices and is available via the Apple App Store and Google Play Store.

“We are excited to expand the availability of KetoAir™ into the UK. This launch builds on our U.S. market launch and represents an important step in growing our footprint,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “Amid the growing adoption of ketogenic and low-carb diets across the UK, we believe KetoAir™ is uniquely positioned to empower individuals in achieving their health and wellness goals. Designed for those pursuing ketogenic lifestyles for weight management, enhanced athletic performance, or therapeutic purposes, the device harnesses advanced nano-sensor technology to deliver precise, real-time metabolic insights with ease and accessibility.”

For more information or to purchase KetoAir™ in the UK starting September 1, 2025, please visit www.KetoAir.uk.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: ALBT) is a developer of precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. Avalon is currently marketing the KetoAir™ breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir^TM is registered with the U.S. Food and Drug Administration as a Class I medical device. The Company also continues to focus on advancing its intellectual property portfolio through existing patent applications. In addition, Avalon owns and operates commercial real estate. For more information about Avalon, please visit www.avalon-globocare.com.

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”).

Additional Information About the Proposed Merger for Investors and Shareholders

This communication relates to the proposed merger (the “proposed Merger”) of Avalon and YOOV Group Holding Limited (“YOOV”). In connection with the proposed Merger, Avalon has filed relevant materials with the U.S. Securities and Exchange Commission (the “SEC”), including a Registration Statement on Form S-4, as amended, that contains a preliminary prospectus and preliminary proxy statement of Avalon (the “proxy statement/prospectus”). This Registration Statement has not yet been declared effective and Avalon has filed or may file other documents regarding the proposed Merger with the SEC. This press release is not a substitute for the proxy statement/prospectus or for any other document that Avalon has filed or may file with the SEC in connection with the proposed Merger. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to Avalon’s stockholders. Investors and security holders will be able to obtain these documents (when available) free of charge from the SEC’s website at www.sec.gov. In addition, investors and stockholders should note that Avalon communicates with investors and the public using its website (https://www.avalon-globocare.com), the investor relations website (https://www.avalon-globocare.com/investors) where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Avalon with the SEC, and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed Merger.

Participants in the Solicitation

Avalon, YOOV and their respective directors and executive officers and other members of management and employees and certain of their respective significant stockholders may be deemed to be participants in the solicitation of proxies from Avalon and YOOV stockholders in respect of the proposed Merger. Information about Avalon’s directors and executive officers is available in Avalon’s Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 31, 2025. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, has been and will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed Merger when they become available. Investors should read the definitive proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC and Avalon as indicated above.

Forward-Looking Statements

Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of its products and the product’s ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission (the “SEC”), accessible through the SEC’s website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com

FAQ

When will Avalon GloboCare (ALBT) launch KetoAir sales in the UK?

Avalon will launch KetoAir sales in the UK on September 1, 2025 through their website www.KetoAir.uk.

What is the KetoAir breathalyzer by Avalon GloboCare (ALBT)?

KetoAir is an FDA-registered handheld breathalyzer that measures breath acetone concentration (BrAce) to track fat metabolism and ketosis for people following ketogenic diets.

Is the Avalon GloboCare KetoAir device compatible with smartphones?

Yes, KetoAir is compatible with both Apple and Android devices and its app is available on both the Apple App Store and Google Play Store.

Who manufactures the KetoAir breathalyzer for Avalon GloboCare?

KetoAir is owned and manufactured by Qi Diagnostics Limited, a nanosensor-based diagnostic technologies company.

What is the FDA registration number for Avalon's KetoAir device?

The KetoAir breathalyzer's FDA registration number is 3026284320.